Show simple item record

dc.contributor.authorDoshi, Peter
dc.date.accessioned2017-05-25T01:11:27Z
dc.date.available2017-05-25T01:11:27Z
dc.date.issued2017-04-06
dc.identifier.citationDoshi, P.(2017). FDA unease about faster drug approval. BMJ 2017;357:j1691. DOI: https://doi.org/10.1136/bmj.j1691en_US
dc.identifier.urihttp://hdl.handle.net/10713/6594
dc.descriptionA little noticed FDA report reveals internal opposition to Trump plans to speed drugs to market. Peter Doshi discusses the concernsen_US
dc.description.urihttp://bmj.com/cgi/content/full/bmj.j1691?ijkey=92Ykz5ZD2eZqZ2M&keytype=ref
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.subjectdrug safety studiesen_US
dc.subjectdrug regulationsen_US
dc.subjectclinical trials, phase 3en_US
dc.subject.lcshUnited States. Food and Drug Administrationen_US
dc.subject.meshClinical Trials as Topicen_US
dc.subject.meshClinical Trial, Phase IIIen_US
dc.titleFDA unease about faster drug approvalen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmj.j1691
dc.identifier.pmid28385688
dc.identifier.ispublishedNoen_US
dc.description.urinameClick here for the free full-text article on publisher’s websiteen_US
refterms.dateFOA2019-02-19T18:15:23Z


Files in this item

Thumbnail
Name:
Doshi_BMJ_FDA_Unease.pdf
Size:
301.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record